Summary Anti-p53 antibodies in sera are known to be products of the host immune response to mutated p53 protein, and are present in some patients with various types of cancer. In this study, we measured serum anti-p53 antibody levels in 52 patients with lung cancer and 63 normal volunteers to determine the relationship between anti-p53 antibody level and clinical features of lung cancer patients. Anti-p53 antibody level was measured by an enzyme-linked immunosorbent assay and expressed as an anti-p53 antibody index, defined as the ratio of absorption of serum sample to that of p53-positive serum. The median anti-p53 antibody index was 6.6 for lung cancer patients, and higher than that in normal volunteers (1.7) (P = 0.0000). For lung cancer patients, significant differences in index levels were found by histology (4.3, n = 25, adenocarcinoma vs 8.7. n = 18, squamous cell carcinoma vs 64.8, n = 2, large-cell carcinoma vs 9.8, n = 7, small-cell carcinoma; P= 0.0109). High anti-p53 antibody index levels were observed for both large-cell carcinoma and small-cell carcinoma. When the cut-off level was set at 7.2, determined using the twice 95% specificity level for normal volunteers, the sensitivities of anti-p53 antibodies were 46.1% for all lung cancers, 28.0% for adenocarcinoma, 55.6% for squamous cell carcinoma, 100% for large-cell carcinoma and 71.4% for small-cell carcinoma. However, there were no significant differences in index level by gender, age, smoking index, presence of previous or concomitant cancer or disease stage. Mulfivariate analysis using a logistic regression model demonstrated that histological type of tumour was a dominant factor associated with elevation of anti-p53 antibody index level (P= 0.0184). These findings suggest that serum anti-p53 antibody index level might be independent of tumour burden and the presence of previous or concomitant cancer in our series of lung cancer patients, but is clearly strongly correlated with tumour histological type.
The p53 tumour-suppressor gene encompasses 16-20 kb of cellular DNA located on the short arm of human chromosome 17 (Levine et al. 1991f . This gene is involved in control of the cell cycle. DNA synthesis and repair. cell differentiation. genomic plasticity and programmed cell death (Harris et al. 1993) . Mutations of the p53 gene are currently the most common genetic alteration identified in human cancers (Levine et al. 1991 : Harris and Hollstein 1993 : Chang et al. 1995 .
The p53 gene product. p53 protein. is generally present at low levels in normal tissues and cannot usually be detected using conventional immunoprecipitation or immunohistochemical methods. How-ever. in more than half of common cancers. dramatic accumulation of p53 protein is readily detected both histochemicallv and by quantitative enzyme-linked immunosorbent assav (ELISA) and immunoblotting technique (Hollstein et al. 1991 : Lesine et al. 1991 . Missense mutations that lead to a prolonged half-life of p53 protein are principally responsible for the detection of this protein (Levine et al. 1991) Mutant p53 proteins are known to be targets of host immune svstems (Craw-fort et al. 1982 ). Examination of serum has shown that some patients with cancers that harbour a mutated p53 allele have mounted a humoral immune response to abnormal levels of p53 protein. Anti-p53 antibodies (anti-p53) have been demonstrated in up to 26% of patients v% ith various malignant conditions. including breast. lung. colorectal and liver tumours. as well as lymphomas (Craw-fort et al. 1982 : Caron de Fromentel et al. 1987 . Davidoff et al. 1992 : Schhchtholz et al. 1992 : Winter et al. 1992 : Labrecque et al. 1993 : Lubin et al. 1993 : Muller et al. 1994 : Chang et al. 1995 . For breast cancer patients. the presence of anti-p53 in serum is significantly correlated with high-grade histologv. historv of second primary cancer and poor prognosis : Peyrat et al. 1995 . In addition. the potential for early diagnosis of cancer bv detection of anti-p53 has been noted. as emergence of serum anti-p53 was demonstrated before clinical detection of cancers among a subset of a non-cancer cohort : Trivers et al. 1995 . 1996 . We assessed serum p53 protein levels in a series of small-cell lung cancer patients in a previous study: however. only a fez of the patients Sue studied exhibited an elevated p53 protein level (Segaawa et al. 1997ai . Therefore. in the present study. xe measured serum anti-p53 levels in patients newtly diagnosed with lung cancer using an ELISA method and examined the relationship between anti-p53 level and clinical features of lung cancer patients in order to determine the clinical significance of serum anti-p53 values for lung cancer patients.
667 All the patients with lung cancer underwent a series of examinations for staging as previously described (Segawa et al, 1997b) , and were classified using the tumour-node-metastasis system (Mountain et al, 1986) Measurement of serum anti-p53 index levels Serum samples were obtained from subjects (at the time of diagnosis in the case of lung cancer patients) and stored at -70'C until measurement. Anti-p53 index levels were determined using an ELISA kit (Dianova, Germany). Briefly. serum samples were diluted 1:100 in the sample dilution buffer prepared with the kit before assay. The samples were added to 96-microtitre wells precoated with human recombinant p53 protein and incubated at 370C for 1 h. After washing, anti-p53 antibodies that attached to the protein of each well were bound by peroxidase-conjugated goat anti-human IgG. Colour was developed with the chromogenic substrate tetramethylbenzidine, and the absorbance of each well was determined using a microplate reader at a wavelength of 450 nm (Bio-rad, USA). The anti-p53 index was calculated using the formula: [A450 (serum sample) -A450 (anti-p53-negative serum)J/[A450 (anti-p53-positive serum) -A450 (anti-p53-negative serum)] x 100. Following the directions given in the manual for this kit, the anti-p53-positive serum was tested for the presence of anti-p53 by immunoblotting assay. All the samples were measured in duplicate. Mean values of anti-p53 indexes for each sample were used for analyses in this study. In addition, the coefficients of variation tested for three samples from normal volunteers ranged from 3.2% to 8.7%.
Immunoblotting analysis of serum antI-3
Fourteen serum samples obtained from lung cancer patients were tested for the presence of anti-p53 by an immunoblotting method. These samples exhibited a consecutively increasing anti-p53 index level in our series ( Figure 1 ). Our immunoblotting procedure was described previously (Segawa et al, 1997a) . Briefly, an aliquot of 1 x 106 p53 protein-positive HEL 92.1.7 cells (American Type Culture Collection, USA) was lysed in phosphate-buffered saline (PBS) containing 0.25 M sucrose, 0.01% ethylenedianiinetetraacetic acid disodium salt, 2 mm phenylmethylsulfonyl fluoride, 0.02% sodium nitride, and 0.5% Nonidet P-40 and ultrasonicated for 40 s. After centrifugation at 10 000 xg for 60 min. I)0 gI of the lysate was combined with the same volume of sample buffer (0.25 M Tris. 20% glycerol. 4% sodium dodecyl sulphate. 0.05% bromophenol blue, 10% S-mercaptoethanol) and boiled for 5 min.
Then. 10 g1 of the sample was loaded into individual wells of a 10% polyacrylamide gel, electrophoretically separated and transferred to nitrocellulose membrane. After blocking with PBS containing 1% skim milk, separated pieces of the membrance were Brfish Joumal of Cancer (1998) 78(5), 667-672 Serum ant-p53 antibodies in lung cancer 669 incubated with individual patient serum (a 1:250 dilution in PBS containing 1% skim milk) at room temperature for 1 h. Mouse monoclonal anti-p53 antibody (1:500 dilution: Dako. Denmark) and PBS containing 1% skim milk were used as positive and negative controls respectively. After washing with PBS containing 0.1% Tween 20. the membranes were incubated with a 1:500 dilution of alkaline phosphatase-conjugated goat antihuman IgG (Jackson Immunoresearch. USA) or of peroxidaseconjugated goat anti-mouse IgG (Tago. USA). Colour was developed with the chromogenic substrates nitrotetrazolium blue or diaminobenzidine.
Statistical analyses
Values are expressed as the median and the 75th and 90th percentiles of anti-p53 index levels. Statistical analyses were performed using the SPSS Base SystemTm' and Advanced
StatisticsT'm programs (SPSS. USA). Except for the chi-square and Fisher's exact probability tests, non-parametric methods were used. The significance of differences between two independent groups was determined by the Mann-Whitney U-test and the significance of differences among more than two groups was determined by Kruskal-Wallis one-way analysis. To estimate the importance of factors associated with elevated serum anti-p53 index level, logistic regression analysis was performed in backward step-wise fashion. Removal testing was based on the probability of the likelihood ratio statistic based on maximum likelihood estimates. A receiver operating characteristics (ROC) curve was constructed using the CLABROC program (Metz. 1991) . Values of P less than 0.05 in two-tailed analyses were considered significant.
RESULTS
Serum anti-p53 index levels in lung cancer patients and normal volunteers The median levels of serum anti-p53 index were 6.6 for patients with lung cancer and 1.7 for normal volunteers (Figure 1 ): there was a statistically significant difference between these two groups (P = 0.0000). although significant differences were also found between the two groups not only in age (P = 0.0000) but also in the proportion of individuals with previous or concomitant cancer (P = 0.0027) ( Table 1) . Among normal volunteers, there were no differences in anti-p53 index level by age (1.5. < 29 years of age vs 2.0. > 29: P = 0.6046). However. a significant difference in level was found by gender (1.1. male vs 2.2. female: P = 0.0001). Among lung cancer patients. there were no differences in anti-p53 index level by gender (8.7. male vs 4.7. female: P = 0.1015). age (4.0. < 68 years of age vs 8.2. > 68: P = 0.1152). smoking index (3.6. smoking index < 600 vs 8.7. 2 600: P = 0.0903). presence of previous or concomitant cancer (6.9 . no vs 0.6. yes: P = 0.1074).
or disease stage (6.9. stage I vs 10.2. iLIAAiHB vs 5.7. IV: P = 0.1611). However, significant differences in index levels were found by histology (4.3. adenocarcinoma vs 8. (box) , median value (horizontal line), and the middle 90% dstribution (whisker line). The dashed lines indicate the cut-off levels of the anti-p53 antibody index (3.6 or 7.2, determined using the 95% specificity level for normal volunteers). Each sensitivity was determined using a cut-off level of 3.6 (t) or 7.2 ( §). The correlation between the anti-p53 antibody index level and result of immunobloting analysis for 14 patients with lung cancer is also demonstrated (0, antip53 antibody-positive by immunoblotting; a, antibody-negative). Adeno, adenocardnoma, large, large-cell carcinoma; normal, normal volunteers; small, small-cell carcinoma; squamous, squamous cell carcinoma British Journal of Cancer (1998) immunoblotting assay. Figure 2 shows some of these results. These positive samples had high anti-p53 index levels (%.5, 76.7. and 52.9 respectively). Antibodies were not detected in the samples with low anti-p53 index levels below 50.0 (Figures 1 and 2 ).
Sensitivity of anti-p53 index level in detection of lung cancer
Except for 20 serum samples with a high anti-p53 index level above the upper limit of measurement (n = 3) or low level below the lower limit (n = 17). the anti-p53 index levels could be continuously plotted in our series of lung cancer patients and normal volunteers. although the presence of antibodies in serum was not confinued for the samples with a low anti-p53 index level by our immunoblotting assay. Therefore. the cut-off value for the serum anti-p53 index was set at 3.6. in accordance with the 95% specificity approach recommended by Klapdor ( 1992) . The sensitivities of the anti-p53 index were 65.4% for all lung cancers. 52.0% for adenocarcinoma. 66.7% for squamous cell carcinoma and 100% for both large-cell carcinoma and small-cell carcinoma (Figure 1 ). The sensitivity of the anti-p53 index for small-cell carcinoma was significantly higher than that for adenocarcinoma (P = 0.0230). In addition. when the cut-off value was set at 7.2. which corresponded to twice the 95% specificity level for normal volunteers. the sensitivities were 46.1% for all lung cancer. 28.0% for adenocarcinoma. 55.6% for squamous cell carcinoma. 100% for large-cell carcinoma and 71.4% for small-cell carcinoma ( Figure  1 ). With this cut-off value, the sensitivity of the anti-p53 index for squamous cell carcinoma was significantly higher than that for adenocarcinoma (P = 0.0359). The ROC curve for the anti-p53 index for patients with lung cancer is shown in Figure 3 . This curve demonstrated that the serum anti-p53 index had both high sensitivity and specificity for the detection of lung cancer in this study. This index thus appears to be useful as a marker of lung cancer at its initial presentation.
Multivariate analysis of factors associated with elevated anti-p53 index level in sera of lung cancer
The factors associated with elevated anti-p53 index level (2 3.6. determined using the 95% specificity level for normal volunteers in this study) for lung cancer patients were further assessed using logistic regression analysis. All the parameters listed in Table 1 were included and analysed in backward step-wise fashion. The model finally selected [X2 (5) = 19.6. P = 0.0015] is shown in Table 2 . In this model, histology was a dominant factor associated with elevated anti-p53 index level (P = 0.0255). Gender. age and smoking index were selected as factors influencing index level. but their probabilities did not reach significance (P = 0.0586. P = 0.0847. P = 0.0911 respectively). In addition, previous or concomitant cancer was selected as a reverse factor. Disease stage was not selected in this regression model. Furthermore. in the model using the cut-off value of 7.2 [X2 (1) = 6.9. P = 0.0084].
histology was a dominant factor associated with elevated anti-p53 index level (P = 0.0184) ( Table 2) .
DISCUSSION
In our prospective study using a series of serum samples obtained from patients newly diagnosed with lung cancer and normal British Journal of Cancer (1998) 78(5) (Crawfort et al. 1982 : Caron de Fromentel et al. 1987 : Davidoff et al. 1992 : Schlichtholz et al. 1992 : Winter et al. 1992 : Labrecque et al. 1993 : Lubin et al. 1993 : Muller et al. 1994 : Chana et al. 1995 . In a lunc cancer series. Schlichtholz et al (1994) reported that anti-p53 antibodies were found in sera in 20.0% of patients with adenocarcinoma. [Schlichtholz et al. 1994 : Trivers et al. 1996 as well as our own. anti-p53 levels determined by ELISA are continuously plotted for :ancer patients and appear to be higher than those in normal control subjects. We therefore believe that the 95%k specificity approach may be clinically useful for the detection of anti-p53. (Sundaresan et al. 1992 ). Therefore. heavy smokin2. which leads to bronchial epithelial dysplasia. might elevate serum anti-p53 index level. In addition. in our study. no correlation was found between elevated serum anti-p53 level and the presence of previous or concomitant cancer. although Mudenda et al ( 1994) did find a positive correlation between these two. A large cohort study will be needed to determine the true nature of this correlation. In conclusion. in our studv using a series of serum samples from patients newly diagnosed with lung cancer. serum anti-p53 index level appeared possibly to be independent of tumour burden and the presence of previous or concomitant cancer. but was stronalv correlated with tumour histological type.
